by Clinical Neuropsychologist Online | Tuesday, December 31, 2024 | Dementia
Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | December 31, 2024 Wiley: Alzheimer’s & Dementia:...
by Clinical Neuropsychologist Online | Tuesday, December 31, 2024 | Dementia
Abstract INTRODUCTION The triggering receptor expressed on myeloid cells 2 (TREM2) arginine-47-histidine (R47H) mutation is a significant risk for Alzheimer’s disease (AD) with unclear mechanisms. Previous studies focused on microglial amyloid-β (Aβ)...
by Clinical Neuropsychologist Online | Tuesday, December 31, 2024 | Dementia
Abstract INTRODUCTION Aggregation of hyperphosphorylated tau (tauopathy) is associated with cognitive impairment in patients with Alzheimer’s disease (AD). In AD, a metabolic shift due to the Warburg effect results in increased lactate production. Lactate can...
by Clinical Neuropsychologist Online | Tuesday, December 31, 2024 | Dementia
Abstract Blood-based biomarkers (BBBMs) for Alzheimer’s disease (AD) have the potential to revolutionize the detection and management of cognitive impairment. AD BBBMs are not currently recommended for use in primary care but may soon be as research demonstrates...
by Clinical Neuropsychologist Online | Monday, December 30, 2024 | Neurorehabilitation
Neurorehabilitation and Neural Repair, Volume 39, Issue 3, Page 226-229, March 2025. Background:Predicting the rate of cognitive and functional decline over the course of Mild Cognitive Impairment (MCI) and Alzheimer’s disease (AD) is vital for advancing clinical care...
